| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
269,764,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
11,686,762 |
Avg
Vol: |
5,279,592 |
| 52
Week Range: |
$76.25 - $76.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bamforth Mark R |
Sr.VP, Corp. Operations & Phar |
• – – |
2009-03-04 |
4 |
B |
$54.54 |
$38,178 |
I/I |
700 |
3,775 |
1.99 |
- |
|
| Cooney Charles L |
Director |
– • – |
2009-02-23 |
4 |
S |
$69.69 |
$418,140 |
D/D |
(6,000) |
15,164 |
|
- |
|
| Wirth Peter |
Exec VP,Legal & Corporate Dev. |
• – – |
2009-01-16 |
4 |
AS |
$66.50 |
$15,439,970 |
D/D |
(232,180) |
6,068 |
|
- |
|
| Wirth Peter |
Exec VP,Legal & Corporate Dev. |
• – – |
2009-01-16 |
4 |
OE |
$29.44 |
$6,835,379 |
D/D |
232,180 |
238,248 |
|
- |
|
| Meeker David P |
ExecVP,Therapeutics,Biosurgery |
• – – |
2008-12-30 |
5 |
GD |
$0.00 |
$0 |
I/I |
120 |
621 |
|
- |
|
| Meeker David P |
ExecVP,Therapeutics,Biosurgery |
• – – |
2008-12-30 |
5 |
GA |
$0.00 |
$0 |
I/I |
120 |
120 |
|
- |
|
| Dzau Victor J |
Director |
– • – |
2008-12-10 |
4 |
B |
$64.80 |
$100,440 |
I/I |
1,550 |
1,550 |
2.1 |
- |
|
| Collier Earl M Jr |
Executive Vice President |
• – – |
2008-12-09 |
5 |
GD |
$0.00 |
$0 |
D/D |
115 |
1,788 |
|
- |
|
| Smith Alan E |
Sr VP,Chief Scientific Officer |
• – – |
2008-12-08 |
4 |
S |
$65.17 |
$3,618,304 |
D/D |
(55,521) |
30,495 |
|
- |
|
| Smith Alan E |
Sr VP,Chief Scientific Officer |
• – – |
2008-12-08 |
4 |
OE |
$29.44 |
$1,634,538 |
D/D |
55,521 |
86,016 |
|
- |
|
| Amello Jason |
|
– – – |
2008-12-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,428 |
|
- |
|
| Berthiaume Douglas A |
Director |
– • – |
2008-11-04 |
4 |
S |
$74.59 |
$835,408 |
D/D |
(11,200) |
66,158 |
|
- |
|
| Moscicki Richard A |
Sr VP,Chief Medical Officer |
• – – |
2008-09-23 |
4 |
AS |
$76.73 |
$2,811,004 |
D/D |
(36,635) |
15,478 |
|
- |
|
| Moscicki Richard A |
Sr VP,Chief Medical Officer |
• – – |
2008-09-23 |
4 |
OE |
$26.50 |
$1,039,038 |
D/D |
36,635 |
52,113 |
|
- |
|
| Meeker David P |
ExecVP,Therapeutics,Biosurgery |
• – – |
2008-08-27 |
5 |
GD |
$0.00 |
$0 |
I/I |
13 |
741 |
|
- |
|
| Meeker David P |
President LSD Therapeutics |
• – – |
2008-08-15 |
4 |
S |
$83.19 |
$1,479,950 |
D/D |
(17,790) |
1,886 |
|
- |
|
| Meeker David P |
President LSD Therapeutics |
• – – |
2008-08-15 |
4 |
OE |
$20.59 |
$366,296 |
D/D |
17,790 |
19,676 |
|
- |
|
| Bamforth Mark R |
Sr.VP, Corp. Operations & Phar |
• – – |
2008-08-14 |
4 |
S |
$81.71 |
$1,571,447 |
D/D |
(19,232) |
158 |
|
- |
|
| Bamforth Mark R |
Sr.VP, Corp. Operations & Phar |
• – – |
2008-08-14 |
4 |
OE |
$41.50 |
$844,208 |
D/D |
19,232 |
19,390 |
|
- |
|
| Smith Alan E |
Senior Vice President |
• – – |
2008-08-14 |
4 |
S |
$82.51 |
$1,237,650 |
D/D |
(15,000) |
30,495 |
|
- |
|
| Smith Alan E |
Senior Vice President |
• – – |
2008-08-14 |
4 |
OE |
$32.52 |
$487,800 |
D/D |
15,000 |
45,495 |
|
- |
|
| Wyzga Michael S |
Executive VP and CFO |
• – – |
2008-08-12 |
4 |
S |
$79.00 |
$2,321,810 |
D/D |
(29,390) |
13,190 |
|
- |
|
| Wyzga Michael S |
Executive VP and CFO |
• – – |
2008-08-12 |
4 |
OE |
$32.52 |
$957,253 |
D/D |
29,390 |
42,580 |
|
- |
|
| Desrosier Thomas |
Sr VP General Counsel |
• – – |
2008-08-07 |
4 |
S |
$78.99 |
$847,168 |
D/D |
(10,725) |
716 |
|
- |
|
| Desrosier Thomas |
Sr VP General Counsel |
• – – |
2008-08-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,725 |
11,441 |
|
- |
|
604 Records found
|
|
Page 9 of 25 |
|
|
